Danish Medicines Council could be a roadblock for sclerosis drug Kesimpta

Kesimpta has not blown the council away, a draft assessment of the Genmab-developed drug’s clinical value suggests.
by mikkel aabenhus hemmingsen, translated by catherine brett

Although sclerosis drug Kesimpta has been on somewhat of a worldwide victory tour, and generated sales of almost DKK 1.5bn (USD 230m) in the first three quarters of this year, the Danish Medicines Council is not convinced of its advantages.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading